← Back to search
CEDARS-SINAI MEDICAL CENTER
WEST HOLLYWOOD, CA, 90048
UnclaimedClaim this profile (free)
Other Than Small Business
Prime contracting experience
2 records from government sources. Past participation is not evidence of current teaming interest.
| Role | Agency | Description | Vehicle | Obligated | Action date | Period |
|---|---|---|---|---|---|---|
| Prime | National Aeronautics and Space Administration National Aeronautics and Space Administration | CEDARS-SINAI'S PHASE 2 INSPA PROPOSAL TITLED "SCALABLE IN-SPACE BIOMANUFACTURING OF STEM CELL THERAPIES" | — | $3,030,000 | Sep 30, 2026 | Sep 30, 2026 – Aug 30, 2030 |
| Prime | National Aeronautics and Space Administration National Aeronautics and Space Administration | IN-SPACE PRODUCTION OF STEM CELL THERAPIES | — | $3,530,300 | Sep 3, 2026 | Sep 21, 2022 – Dec 30, 2026 |
Contract vehicles are shown only when present in the source record. Linked award numbers and vehicles open the authoritative record on USAspending.gov.
Subcontracting experience
5 records from government sources. Past participation is not evidence of current teaming interest.
| Role | Agency | Description | Vehicle | Obligated | Action date | Period |
|---|---|---|---|---|---|---|
| Subcontractor | National Aeronautics and Space Administration | STATEMENT OF WORK FOR PROJECT ENTITLED “IN SPACE BIOMANUFACTURING OF INDUCED PLURIPOTENT STEM
CELLS FOR REGENERATIVE MEDICINE APPLICATIONS ON EARTH”
BACKGROUND AND EXPERIENCE:
I FOUNDED THE TRANSPLANT AND STEM CELL IMMUNOBIOLOGY (TSI) LAB IN 2009, AND I AM CURRENTLY
APPOINTED AS ACTING PROFESSOR IN THE DEPARTMENT OF SURGERY AT CEDARS SINAI. I HAVE A SUCCESSFUL
TRACK RECORD OF OVER 20 YEARS IN PERFORMING RESEARCH FOCUSED ON PLURIPOTENT STEM CELLS (PSC)
IMMUNOBIOLOGY AND PRE-CLINICAL AS WELL AS TRANSLATIONAL AND CLINICAL STUDIES. WE USE A
COMBINATION OF MOLECULAR/CELLULAR BIOLOGY, GENOMIC/EPIGENOMIC PROFILING, TISSUE ENGINEERING,
AND MOLECULAR IMAGING TECHNOLOGIES TO BETTER UNDERSTAND STEM CELL BIOLOGY IN VITRO AND IN VIVO.
WE HAVE MADE SIGNIFICANT CONTRIBUTIONS TO SPACEFLIGHT MEDICINE STUDYING THE EFFECT OF
MICROGRAVITY AND SPACEFLIGHT ON VASCULAR HEALTH, IMMUNE CELLS, AND STEM CELLS SUPPORTED BY
NASA, NIH/CASIS AND NSF GRANTS. OUR RESEARCH WAS ON 3 DIFFERENT SPACEX MISSIONS ON THE
ISS.
PROPOSED EXPERIMENT:
THE “IN SPACE BIOMANUFACTURING OF INDUCED PLURIPOTENT STEM CELLS FOR REGENERATIVE MEDICINE
APPLICATIONS ON EARTH” PROJECT ATTEMPTS TO UTILIZE THE UNIQUE ENVIRONMENT OF MICROGRAVITY TO
DEVELOP IPSC MANUFACTURING PROCESSES AT LARGER SCALE.
PROPOSED WORKPLAN:
THE SCHREPFER LAB AT CEDARS SINAI WILL PROVIDE IPSC, PROCESS DEVELOPMENT AND ANALYTICS SUPPORT
FOR PROJECT GOALS ASSOCIATED WITH FLIGHTS 1 AND 2 (TABLE 1).
FLIGHT 1:
1. WORK CLOSELY WITH BIOSERVE TEAM TO OPTIMIZE SMALL SCALE IPSC CULTURE SYSTEMS
COMPATIBLE WITH CURRENT HARDWARE.
2. CONDUCT INDEPENDENT LAB TESTING OF THE FLIGHT PROTOCOL IN CEDAR-SINAI’S LABS WITH
BIOSERVE PROVIDED FLIGHT HARDWARE.
3. PERFORM ANALYTICS FOR ALL SAMPLES GENERATED DURING GROUND AND ISS STUDIES, INCLUDING:
FLOW CYTOMETRY, QPCR, GENETIC ASSESSMENT, AND RNASEQ.
FLIGHT 2:
1. WORK CLOSELY WITH BIOSERVE TEAM TO OPTIMIZE LARGE SCALE IPSC AND IPSC-HE CULTURE
SYSTEMS COMPATIBLE WITH NEWLY DEVELOPED HARDWARE.
2. CONDUCT INDEPENDENT LAB TESTING OF THE FLIGHT PROTOCOL IN CEDAR-SINAI’S LABS WITH
BIOSERVE PROVIDED FLIGHT HARDWARE.
3. PERFORM ANALYTICS FOR ALL SAMPLES GENERATED DURING GROUND AND ISS STUDIES, INCLUDING:
FLOW CYTOMETRY, QPCR, GENETIC ASSESSMENT, AND RNASEQ. 1567592 Parent award context Parent award agency: National Aeronautics and Space Administration · National Aeronautics and Space Administration Parent award NAICS: 541715 Parent award performance state: CO Parent award description: IN SPACE PRODUCTION OF IPSC-DERIVED CAR-T CELLS FOR CLINICAL APPLICATIONS View parent award on USAspending | 80JSC025DA003USAspending | $429,015 | Jun 30, 2026 | — – — |
| Subcontractor | National Aeronautics and Space Administration | PROCURED GOODS AND/OR SERVICES BETWEEN 01-OCT-24 AND 30-SEP-26 IN SUPPORT OF CONTRACT SOW. P010383197-0 Parent award context Parent award agency: National Aeronautics and Space Administration · National Aeronautics and Space Administration Parent award NAICS: 541330 Parent award performance state: TX Parent award description: CARGO MISSION CONTRACT 4 (CMC4) View parent award on USAspending | — | $399,200 | Jun 8, 2026 | — – — |
| Subcontractor | Department of Health and Human Services | CANCER PREVENTION AGENT DEVELOPMENT PROGRAM: EARLY PHASE CLINICAL RESEARCH SP0016040 60045323 TO 12 CEDARS- Parent award context Parent award agency: Department of Health and Human Services · National Institutes of Health Parent award NAICS: 541712 Parent award performance state: IL Parent award description: IGF::OT::IGF STATIN THERAPY TO REDUCE DISEASE PROGRESSION FROM LIVER CIRRHOSIS TO CANCER View parent award on USAspending | HHSN261201200035IUSAspending | $88,420 | Dec 21, 2022 | — – — |
| Subcontractor | Department of Health and Human Services | PURPOSES: TO DE-OBLIGATE UNEXPENDED APPROPRIATED FUNDS FOR FISCAL YEAR 2016 IN ACCORDANCE WITH USC
1552(A); AND TO EXTEND THE PERIOD OF PERFORMANCE THROUGH 9/14/2023 TO COMPLETE PATIENT TREATMENT. SP0016040 60048310 TO 13 GUMC Parent award context Parent award agency: Department of Health and Human Services · National Institutes of Health Parent award NAICS: 541712 Parent award performance state: IL Parent award description: IGF::OT::IGF IMMUNOGENICITY OF NONAVALENT HPV VACCINE ADMINISTERED PRIOR TO LIVING DONOR RENAL TRANSPLANTATION IN ADULT WOMEN: A PROSPECTIVE, SINGLE-ARM, MULTI-CENTER CLINICAL TRIAL View parent award on USAspending | HHSN261201200035IUSAspending | -$114,311 | Mar 18, 2022 | — – — |
| Subcontractor | Department of Health and Human Services | THE OBJECTIVE OF THIS RANDOMIZED DOUBLE-BLINDED, PLACEBO-CONTROLLED PHASE II TRIAL IS TO EXAMINE THE EFFECTS OF SIMVASTATIN USE VERSUS PLACEBO AFTER 6 MONTHS OF TREATMENT ON LIVER DISEASE PROGRESSION IN 80 PATIENTS WITH LIVER CIRRHOSIS WHO HAVE A CURRENT MODEL FOR END-STAGE LIVER DISEASE (MELD) ‰¤ 20 AND NO EVIDENCE OF HEPATOCELLULAR CARCINOMA (HCC). SP0016040 60045323/SP0016040 600 Parent award context Parent award agency: Department of Health and Human Services · National Institutes of Health Parent award NAICS: 541712 Parent award performance state: IL Parent award description: IGF::OT::IGF STATIN THERAPY TO REDUCE DISEASE PROGRESSION FROM LIVER CIRRHOSIS TO CANCER View parent award on USAspending | HHSN261201200035IUSAspending | $90,980 | Oct 5, 2021 | — – — |
Contract vehicles are shown only when present in the source record. Linked award numbers and vehicles open the authoritative record on USAspending.gov.
Agencies supported
- National Aeronautics and Space AdministrationGov-sourced
Government-sourced data comes from SAM.gov, SBA and USAspending.gov and is attributed to its source. Items marked company-reported were provided by the company and are verified by FedSub only where labeled. FedSub is a private company and is not affiliated with SBA, GSA/SAM.gov, or any government agency.